KRAS and familial pancreatic carcinoma: In addition, the ERK inhibitor temuterkib has shown promise in BRAF- and KRAS-mutant pancreatic cancer models, tested alone or in combination with HCQ (NCT04386057), and paricalcitol and HCQ or in combination with GnP (NCT04524702) in advanced or mPDAC patients.